BioCardia, Inc.

BCDA Healthcare Biotechnology

BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024.

EPS
+67.5%
Free cash flow
−5.15%

Quarter to June 2026, against a year earlier

0.87 0.02 −2.25%
Market cap
$13.5M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
4/9
Altman Z
−74.83
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.09 0.41 1.12 1.62
Net Debt/EBITDA
2.54 0.43 1.24 3.56
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.14) (0.15) (0.23) (0.27)
Book value per Share
0.22 (0.10) 0.08 0.42
Free Cash Flow
(1.73) (1.66) (2.50) (1.67)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026